ABBV vs ABT
AbbVie Inc. vs Abbott Laboratories · Updated Nov 13, 2026
ABBV — 13 winsABT — 10 wins
Price Performance
ABBV +26.76%ABT -17.03%
Performance
| ABBV | ABT | |
|---|---|---|
| 1 Month | +4.21% | +4.10% |
| 3 Months | +18.42% | -3.64% |
| 6 Months | +40.16% | +26.26% |
| YTD | +29.29% | -14.44% |
| 1 Year | +31.20% | -14.85% |
| 3 Year | +107.81% | +12.84% |
| 5 Year | +152.37% | -16.71% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | +28.4% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
| ABT | -13.6% | +10.4% | +3.0% | +0.5% | -21.0% | +29.0% | +25.9% | +25.0% | +23.0% | +46.1% | -10.5% | +0.0% |
Valuation
| ABBV | ABT | |
|---|---|---|
| P/E Ratio | 144.86 | 29.86 |
| Forward P/E | 20.80 | 19.99 |
| PEG Ratio | 1.23 | 5.74 |
| P/S Ratio | 8.30 | 4.20 |
| P/B Ratio | 18.96 | 2.87 |
| EV/EBITDA | 34.57 | 20.67 |
Financials
| ABBV | ABT | |
|---|---|---|
| EPS (TTM) | $2.04 | $3.59 |
| Gross Margin | +83.54% | +56.28% |
| Operating Margin | +31.56% | +16.50% |
| Net Margin | +4.66% | +9.65% |
| ROE | +13.23% | +9.50% |
| ROA | +2.67% | +5.07% |
| Debt/Equity | 2.65 | 0.52 |
Growth
| ABBV | ABT | |
|---|---|---|
| Revenue Growth YoY | +12.43% | +7.78% |
| Revenue Growth QoQ | -9.72% | -2.57% |
| EPS Growth YoY | -45.83% | -18.24% |
| EPS Growth QoQ | -61.76% | -39.22% |
Technical
| ABBV | ABT | |
|---|---|---|
| RSI (14) | 65.08 | 54.72 |
| % From 20-Day SMA | +2.16% | +0.39% |
| % From 50-Day SMA | +7.50% | +3.16% |
| % From 200-Day SMA | +22.88% | +5.59% |
| % From 52-Week High | -2.48% | -18.81% |
| % From 52-Week Low | +54.87% | +30.77% |
Analyst Ratings
ABBV
Buy(44 analysts)
Strong SellHoldStrong Buy
Price Target
$308.88
+6.28% upside
ABT
Buy(28 analysts)
Strong SellHoldStrong Buy
Price Target
$121.36
+10.05% upside
Overview
| ABBV | ABT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| Exchange | NYSE | NYSE |
| Market Cap | $521.41B | $189.39B |
| Shares Outstanding | 1.77B | 1.73B |
| Avg Volume (10D) | 5.99M | 8.90M |
| Dividend Yield | 2.35% | 2.30% |
Frequently Asked Questions
Is ABBV or ABT a better buy right now?
Based on 23 comparable metrics, ABBV leads in 13 categories while ABT leads in 10. ABBV has a consensus analyst rating with 44 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, ABBV or ABT?
Over the past year, ABBV returned +31.20% compared to ABT's -14.85%. In the short term (1 month), ABBV returned +4.21% vs ABT's +4.10%.
Is ABBV or ABT more expensive?
ABBV trades at a P/E of 144.86 compared to ABT's 29.86. On a price-to-sales basis, ABBV trades at 8.30x vs ABT's 4.20x. Forward P/E: ABBV at 20.80 vs ABT at 19.99.
Which stock has higher growth, ABBV or ABT?
ABBV's revenue grew +12.43% year-over-year compared to ABT's +7.78%. EPS growth: ABBV at -45.83% vs ABT at -18.24%.
Do ABBV and ABT pay dividends?
ABBV pays a dividend with a yield of 2.35%. ABT pays a dividend with a yield of 2.30%.
Which stock do analysts prefer, ABBV or ABT?
ABBV has 44 analysts with a target price of $308.88 (+6.28% upside). ABT has 28 analysts with a target of $121.36 (+10.05% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.